MEDIA ADVISORY, Oct. 20, 2006 (PRIMEZONE) --
What: Ginger Graham, CEO of Amylin Pharmaceuticals (AMLN) will preside over the opening bell. Where: NASDAQ MarketSite -- 4 Times Square -- 43rd & Broadway -- Broadcast Studio When: Monday October 23rd, 2006 at 9:30 a.m. EDT Contacts: Courtney Walker Vice President, Health Edelman (212) 704-8102 Courtney.Walker@edelman.com NASDAQ MarketSite: Stephanie Lowenthal: (646) 441-5220
The opening bell is available from 9:20 a.m. to 9:35 a.m. on uplink IA6 C band / transponder 24, downlink frequency 4180 horizontal. The feed can also be found on Waterfront fiber 1623. If you have any questions, please contact Stephanie Lowenthal at (646) 441-5220.
To obtain a hi-resolution photograph of the Market Open, please go to http://www.nasdaq.com/reference/marketsite_events.stm and click on the market open of your choice.
About Amylin Pharmaceuticals (AMLN):
Amylin Pharmaceuticals is a biopharmaceutical company committed to improving lives through the discovery, development and commercialization of innovative medicines. Amylin has developed and gained approval for two first-in-class medicines for diabetes, SYMLIN(R) (pramlintide acetate) injection and BYETTA(R) (exenatide) injection. Amylin's research and development activities leverage the company's expertise in metabolism to develop potential therapies to treat diabetes, obesity and cardiovascular disease. Amylin is located in San Diego, California with over 1250 employees nationwide.
Further information on Amylin Pharmaceuticals is available at www.amylin.com.
In This StoryNDAQ
Nasdaq Press Center
Read the latest press releases, request a press kit, and get in touch with our press team.